Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
KMTS 
Kestra Medical Technologies, Ltd. Common Stock (KMTS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: KMTS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $27.5
1 Year Target Price $27.5
| 4 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 19.78% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.24B USD | Price to earnings Ratio - | 1Y Target Price 27.5 |
Price to earnings Ratio - | 1Y Target Price 27.5 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 13.25 - 27.71 | Updated Date 09/27/2025 |
52 Weeks Range 13.25 - 27.71 | Updated Date 09/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.92 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -159.67% | Operating Margin (TTM) -136.52% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1236950421 | Price to Sales(TTM) 23.65 |
Enterprise Value 1236950421 | Price to Sales(TTM) 23.65 | ||
Enterprise Value to Revenue 23.5 | Enterprise Value to EBITDA - | Shares Outstanding 51348700 | Shares Floating 22240643 |
Shares Outstanding 51348700 | Shares Floating 22240643 | ||
Percent Insiders 6.09 | Percent Institutions 87.32 |
Upturn AI SWOT
Kestra Medical Technologies, Ltd. Common Stock
Company Overview
History and Background
Kestra Medical Technologies is a company focused on developing innovative neuromodulation therapies for unmet needs in heart failure and other chronic conditions. Specific founding year and early milestones require more detailed information; however, recent focus is on its cardiac neuromodulation system.
Core Business Areas
- Cardiac Neuromodulation: Developing and commercializing implantable neuromodulation devices designed to treat heart failure by modulating the nervous system's influence on cardiac function.
Leadership and Structure
Due to lack of further data, information on the leadership and organizational structure is not available.
Top Products and Market Share
Key Offerings
- Kestra System: An investigational cardiac neuromodulation system designed to reduce the symptoms of heart failure by targeting the autonomic nervous system. Current status is clinical trials are under way. Detailed market share data is unavailable as the product is still under development and in clinical trials. Competitors include companies working on similar neuromodulation approaches for heart failure, such as those developing vagal nerve stimulation (VNS) or spinal cord stimulation (SCS) therapies.
Market Dynamics
Industry Overview
The neuromodulation market for cardiovascular diseases is growing, driven by the increasing prevalence of heart failure and the need for effective therapies beyond medication and device-based interventions.
Positioning
Kestra Medical Technologies aims to establish itself as a leader in cardiac neuromodulation by developing innovative and clinically effective therapies for heart failure and related conditions.
Total Addressable Market (TAM)
The TAM for cardiac neuromodulation is estimated to be billions of dollars, encompassing a significant portion of the heart failure treatment market. Kestra is positioned to capture a share of this market with its proprietary neuromodulation system; however, the exact market capture percentage is dependent on positive clinical trial outcomes, regulatory approvals, and successful commercialization strategy.
Upturn SWOT Analysis
Strengths
- Innovative technology
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited commercial presence
- Dependence on clinical trial outcomes
- Funding requirements
Opportunities
- Expanding market for cardiac neuromodulation
- Potential for strategic partnerships
- Regulatory approvals and market access
Threats
- Competition from established medical device companies
- Clinical trial failures
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- BSX
- MDIT
- NVCR
Competitive Landscape
Kestra faces competition from established medical device companies with broader product portfolios and greater financial resources. Kestra's advantage lies in its innovative technology and focus on cardiac neuromodulation.
Growth Trajectory and Initiatives
Historical Growth: Since the company is private, this information is not publicly available.
Future Projections: Future growth is dependent on the successful completion of ongoing clinical trials and regulatory approvals. Analyst estimates are unavailable due to the company's private status.
Recent Initiatives: Focus on clinical trials for Kestra System in heart failure patients.
Summary
Kestra Medical Technologies is a promising company in the cardiac neuromodulation space, focusing on an innovative treatment for heart failure. The success of their product depends heavily on favorable clinical trial outcomes and regulatory approvals. They face competition from larger medical device companies and require funding to support ongoing development. Their focus on cardiac neuromodulation presents a significant opportunity, but execution is crucial for success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Clinical Trial Data
Disclaimers:
The information provided is based on publicly available data and industry analysis. Financial data is limited due to the company's private status. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kestra Medical Technologies, Ltd. Common Stock
Exchange NASDAQ | Headquaters Kirkland, WA, United States | ||
IPO Launch date 2025-03-06 | Founder, President, CEO & Director Mr. Brian Webster | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 330 | Website https://kestramedical.com |
Full time employees 330 | Website https://kestramedical.com | ||
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company's develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its platform provides ASSURE WCD, a wearable cardioverter defibrillator used to protect patients at an elevated risk of sudden cardiac arrest; and a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.